27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- Halozyme Therapeutics Inc (NASDAQ:HALO) reported Q3 revenue of $115.8 million compared to $65.3 million a year ago, beating the consensus of $101.94 million.
- The increase is attributable to higher royalty revenue from subcutaneous Darzalex (daratumumab) and increased product sales.
- Revenue for the quarter included $58.6 million in royalties, an increase of 145%.
- Adjusted EPS of $0.55 came in above the consensus of $0.42.
- Q3 results include substantially reversing all of the valuation allowance recorded against the Company's deferred tax assets.
- The reversal recognized a non-cash income tax benefit during the quarter of $142.5 million, or $0.97 in diluted EPS.
- The operating margin expanded from 61.7% to 65.3%.
- Cash, cash equivalents, and marketable securities were $815.9 million.
- FY21 Guidance: Halozyme expects revenues of $430 million - $445 million, up from prior guidance of $425 million - $445 million.
- Expects adjusted EPS of $1.90 - $2.00, up from $1.85 - $2.00 guided previously.
- Forecasts operating income of $265 million - $280 million, up 84% - 94% Y/Y.
- Price Action: HALO shares are up 0.46% at $39.67 during the market session on the last check Wednesday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!